And 3 months later...
There are plenty of examples of drugs being successful second to market. The point I was making is the expected revenues are much less. Look what 3-months did for PD1 inhibitors. For an already small OV market in melanoma, what do you think a 2nd place OV therapy will generate?
Seems I am doing more research into OV therapies than most of the people here. A lot of hope here - let the data tell the story.
Why IMU is a multi multi bagger, page-22297
-
- There are more pages in this discussion • 2,687 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.8¢ | 5.6¢ | $1.040M | 18.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1917207 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 653942 | 7 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |